Cited by 185Inhalation and Respiratory Drug DeliveryTuberculosis Research and EpidemiologyAdvanced Drug Delivery Systems

The DOI matches its Crossref record; 117 of the 121 references it cites were found in a registry or an index.

Pulmonary drug delivery systems for tuberculosis treatment

Pham, Dinh-Duy, Fattal, Elias, Tsapis, Nicolas·2015·International Journal of Pharmaceutics

DOI 10.1016/j.ijpharm.2014.12.009

Open this paper in CoChat — free account

Abstract

Tuberculosis (TB) remains a major global health problem as it is the second leading cause of death from an infectious disease worldwide, after the human immunodeficiency virus (HIV). Conventional treatments fail either because of poor patient compliance to the drug regimen or due to the emergence of multidrug-resistant tuberculosis. The aim of this review is to give an update on the information available on tuberculosis, its pathogenesis and current antitubercular chemotherapies. Direct lung delivery of anti-TB drugs using pulmonary delivery systems is then reviewed since it appears as an interesting strategy to improve first and second line drugs. A particular focus is place on research performed on inhalable dry powder formulations of antitubercular drugs to target alveolar macrophages where the bacteria develop. Numerous studies show that anti-TB drugs can be incorporated into liposomes, microparticles or nanoparticles which can be delivered as dry powders to the deep lungs for instantaneous, targeted and/or controlled release. Treatments of infected animals show a significant reduction of the number of viable bacteria as well as a decrease in tissue damage. These new formulations appear as interesting alternatives to deliver directly drugs to the lungs and favor efficient TB treatment.

Integrity signals

Registry

Crossref · 10.1016/j.ijpharm.2014.12.009

Cites

117 of 117 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Global tuberculosis report (2014)
Gabbasova, L. A., & Who, E. R. E. (2014) · Cited by 12,702
Aerosol Technology Properties, Behavior, and Measurement of Airborne Particles
Laucks, M. L. (2000) · Journal of Aerosol Science · doi:10.1016/s0021-8502(99)00571-6 · Cited by 3,426
American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: Treatment of Tuberculosis
Blumberg, H. M., Burman, W. J., Chaisson, R. E., Daley, C. L., Etkind, S. C., Friedman, L. N., Fujiwara, P., Grzemska, M., Hopewell, P. C., Iseman, M. D., et al. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.167.4.603 · Cited by 1,936
Diagnostic Standards and Classification of Tuberculosis in Adults and Children: This Official Statement of the American Thoracic Society and the Centers for Disease Control and Prevention was Adopted by the ATS Board of Directors, July 1999. This Statement was endorsed by the Council of the Infectious Disease Society of America, September 1999
(2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.161.4.16141 · Cited by 1,524
Large Porous Particles for Pulmonary Drug Delivery
Edwards, D. A., Hanes, J. S., Caponetti, G., Hrkach, J. S., Ben-Jebria, A., Eskew, M. L., Mintzes, J. D., Deaver, D. R., Lotan, N., & Langer, R. (1997) · Science · doi:10.1126/science.276.5320.1868 · Cited by 1,184
Deposition of particles in the human respiratory tract in the size range 0.005–15 μm
Heyder, J., Gebhart, J., Rudolf, G., Schiller-Scotland, C. F., & STAHLHOFEN, W. (1986) · Journal of Aerosol Science · doi:10.1016/0021-8502(86)90035-2 · Cited by 1,034
Global Tuberculosis Control 2011, WHO Report 2011
Behera, D. (2012) · The Indian Journal of Medical Research · Cited by 1,022
Administration of substances to laboratory animals: routes of administration and factors to consider.
Turner, P. V., Brabb, T., Pekow, C. A., & Vasbinder, M. A. (2011) · PubMed Central · Cited by 982
Tuberculosis: Pathogenesis, Protection and Control
(1996) · Nature Medicine · doi:10.1038/nm0296-244b · Cited by 977
Development of Nanoparticles for Antimicrobial Drug Delivery
Zhang, L., Pornpattananangkul, D., Hu, C.-M., & Huang, C.-W. (2010) · Current Medicinal Chemistry · doi:10.2174/092986710790416290 · Cited by 904

Show all 121 references

Research works printed but not linked: 2

Kundawala, 2012, Treating tuberculosis with chitosan microparticles loaded with rifampicin as respirable powder for pulmonary delivery Indian, J. Novel Drug Deliv., 4, 57
Garcia-Contreras, 2007, Inhaled large porous particles of capreomycin for treatment of tuberculosis in a guinea pig model, Antimicrob. Agents Chemother., 51, 2830, 10.1128/AAC.01164-06 · DOI

Sorted by citations

Items 101–185 of 185

Review of inhalable nanoparticles for the pulmonary delivery of anti-tuberculosis drugs
Ramachandran, S., Prakash, P., Mohtar, N., Kumar, K. S., & Parumasivam, T. (2023) · Pharmaceutical Development and Technology · doi:10.1080/10837450.2023.2279691 · Cited by 16
Current advancements in nanoparticles for vaccines and drug delivery for the treatment of tuberculosis
Sharma, D. K. (2025) · Journal of Microbiological Methods · doi:10.1016/j.mimet.2025.107138 · Cited by 15
Inhalable hybrid nanocarriers for respiratory disorders
Maurya, P., Singh, S., & Saraf, S. A. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-820658-4.00013-3 · Cited by 13
Airway administration of a highly versatile peptide-based liposomal construct for local and distant antitumoral vaccination
Kakhi, Z., Frisch, B., Bourel‐Bonnet, L., Hemmerlé, J., Pons, F., & Heurtault, B. (2015) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2015.11.027 · Cited by 13
Oral Administration of Nanoparticles-Based TB Drugs
Magalhães, J., Vieira, A. C. C., Santos, S. G., Pinheiro, M., & Reis, S. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-52725-5.00016-2 · Cited by 13
Liposomal drug delivery to the lungs: a post covid-19 scenario
Krishna, S. S., Sudheesh, M. S., & Viswanad, V. (2023) · Journal of Liposome Research · doi:10.1080/08982104.2023.2199068 · Cited by 13
Harnessing miRNAs: A Novel Approach to Diagnosis and Treatment of Tuberculosis
Doghish, A. S., Abulsoud, A. I., Nassar, Y. A., Nasr, S. M., Mohammed, O. A., Abdel‐Reheim, M. A., Rizk, N. I., Lutfy, R. H., Mageed, S. S. A., Ismail, M. S., et al. (2025) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.70119 · Cited by 13
Simultaneous HPLC assay for pretomanid (PA-824), moxifloxacin and pyrazinamide in an inhaler formulation for drug-resistant tuberculosis
Momin, M. A. M., Thien, S. J., Krittaphol, W., & Das, S. C. (2016) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2016.11.046 · Cited by 12
Dendrimer-based drug delivery systems for tuberculosis treatment
Shukla, R., Sethi, A., Handa, M., Mohan, M., Tripathi, P. K., & Kesharwani, P. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-819811-7.00010-2 · Cited by 11
Antimicrobial Activity of Schinopsis brasiliensis Engler Extract-Loaded Chitosan Microparticles in Oral Infectious Disease
Sette‐de‐Souza, P. H., de Santana, C. P., Amaral-Machado, L., Duarte, M. C. T., de Medeiros, F. D., Véras, G., & de Medeiros, A. C. D. (2020) · AAPS PharmSciTech · doi:10.1208/s12249-020-01786-x · Cited by 11
Resistant Tuberculosis: the Latest Advancements of Second-line Antibiotic Inhalation Products
Rossi, I., Bettini, R., & Buttini, F. (2021) · Current Pharmaceutical Design · doi:10.2174/1381612827666210122143214 · Cited by 11
Current nanotechnological strategies using lipids, carbohydrates, proteins and metal conjugates-based carrier systems for diagnosis and treatment of tuberculosis — A review
Nagarajan, U., Kanth, S. V., & Saravanan, N. (2022) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2022.12.087 · Cited by 15
Pyrazinamide-loaded poly(lactide-co-glycolide) nanoparticles: Optimization by experimental design
Pham, D.-D., Fattal, E., & Tsapis, N. (2015) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2015.07.006 · Cited by 11
Self-citation
Preparation, characterization, and in vitro evaluation of isoniazid and rifampicin‐loaded archaeosomes
Attar, A., Bakir, C., Yüce‐Dursun, B., Demir, S., Çakmakçı, E., Danış, Ö., Birbir, M., & Ogan, A. (2017) · Chemical Biology & Drug Design · doi:10.1111/cbdd.13066 · Cited by 11
Applications of Chitosan in Pulmonary Drug Delivery
Guan, X., & Zhang, W. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.87932 · Cited by 11
Introduction to Chronic Respiratory Diseases: A Pressing Need for Novel Therapeutic Approaches
Chan, Y., Ng, S. W., Liew, H. S., Pua, L. J. W., Soon, L., Lim, J. S., Dua, K., & Chellappan, D. K. (2021) · Springer eBooks · doi:10.1007/978-981-33-6850-7_2 · Cited by 11
Appraisal of fluoroquinolone-loaded carubinose-linked hybrid nanoparticles for glycotargeting to alveolar macrophages
Maurya, P., Saklani, R., Singh, S., Nisha, R., Pal, R. R., Mishra, N., Singh, P., Kumar, A., Chourasia, M. K., & Saraf, S. A. (2021) · Drug Delivery and Translational Research · doi:10.1007/s13346-021-01055-9 · Cited by 11
Lung-Derived Selectins Enhance Metastatic Behavior of Triple Negative Breast Cancer Cells
Khan, S. U., Xia, Y., Goodale, D. B., Schoettle, G., & Allan, A. L. (2021) · Biomedicines · doi:10.3390/biomedicines9111580 · Cited by 10
Respirable konjac glucomannan microparticles as antitubercular drug carriers: Effects of in vitro and in vivo interactions
Guerreiro, F., Pontes, J. F., Gaspar, M. M., da Costa, A. M. R., Faleiro, M. L., & Grenha, A. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.125838 · Cited by 10
Excipient-free isoniazid aerosol administration in mice: Evaporation-nucleation particle generation, pulmonary delivery and body distribution
Valiulin, S. V., Onischuk, A. A., Baklanov, A. M., Dubtsov, S. N., An’kov, S. V., Tolstikova, T. G., Plokhotnichenko, M. E., Dultseva, G. G., & Mazunina, P. S. (2019) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2019.03.050 · Cited by 10
Current Diagnostics Tools of Tuberculosis: Challenges And Opportunities
Etim, N. G., Mirabeau, T. Y., Olorode, O. A., Nwodo, M. U., & Izah, S. C. (2023) · ES General · doi:10.30919/esg1059 · Cited by 9
The Importance of Interactions Between Carrier and Drug Particles for the Application in Dry Powder Inhalers
Zellnitz, S., Renner, N., Cui, Y., Scherließ, R., Sommerfeld, M., Steckel, H., & Urbanetz, N. A. (2019) · Springer eBooks · doi:10.1007/978-3-030-15899-6_16 · Cited by 9
Development and Characterization of Linezolid loaded Biocompatible Solidlipid based Nanocarrier for Enhanced Lung Deposition and Anti-tubercular Activity: Next Generation tailor-made Carrier for Dry Powder Inhaler
Kamble, R. N., Kausar, E., Kawadiwale, M. S., & Mali, A. (2023) · Current Indian Science · doi:10.2174/2210299x01666230508103042 · Cited by 8
Development of Co-Amorphous Systems for Inhalation Therapy—Part 1: From Model Prediction to Clinical Success
Fröhlich, E., Bordoni, A., Mohsenzada, N., Mitsche, S., Schröttner, H., & Zellnitz, S. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17070922 · Cited by 8
Applications of Inorganic Nanomaterials against Tuberculosis: A Comprehensive Review
Dastidar, D. G., Roy, A., Ghosh, G., & Mandal, S. (2024) · Current Drug Delivery · doi:10.2174/0115672018295247240426055330 · Cited by 9
Pyrazinoic acid-Poly(malic acid) biodegradable nanoconjugate for efficient intracellular delivery
Carneiro, S. P., Moine, L., Tessier, B., Nicolas, V., dos Santos, O. D. H., & Fattal, E. (2019) · Precision Nanomedicine · doi:10.33218/prnano2(3).190523.1 · Cited by 8
Self-citation
Electrospray of core–shell micro drug carriers with various experimental and material parameters
Wang, C. C., & Zhou, Y. (2025) · The International Journal of Advanced Manufacturing Technology · doi:10.1007/s00170-025-15279-3 · Cited by 7
Optimization, In Vitro, and In Silico Characterization of Theophylline Inhalable Powder Using Raffinose-Amino Acid Combination as Fine Co-Spray-Dried Carriers
Party, P., Soliman, L., Nagy, A., Farkas, Á., & Ambrus, R. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17040466 · Cited by 7
Chitosan Microparticles Loaded with New Non-Cytotoxic Isoniazid Derivatives for the Treatment of Tuberculosis: In Vitro and In Vivo Studies
Dragostin, I., Dragostin, O.-M., Iacob, A.-T., Drăgan, M., Chițescu, C. L., Confederat, L. G., Zamfir, A.-S., Tatia, R., Stan, C. D., & Zamfir, C. L. (2022) · Polymers · doi:10.3390/polym14122310 · Cited by 7
In vitro performances of novel co-spray-dried azithromycin/rifampicin microparticles for Rhodococcus equi disease treatment
Rampacci, E., Marenzoni, M. L., Chiaradia, E., Passamonti, F., Ricci, M., Pepe, M., Coletti, M., & Giovagnoli, S. (2018) · Scientific Reports · doi:10.1038/s41598-018-30715-z · Cited by 7
Nanostructured lipid carrier-based drug delivery systems for tuberculosis treatment
Carneiro, S. P., & dos Santos, O. D. H. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-819811-7.00012-6 · Cited by 7
Antibacterial activity of Amikacin-immobilized detonation nanodiamond
Solomatin, A. S., Yakovlev, R. Y., Efremenkova, O. V., Sumarukova, I. G., Kulakova, I. I., & Лисичкин, Г. В. (2017) · Nanosystems Physics Chemistry Mathematics · doi:10.17586/2220-8054-2017-8-4-531-534 · Cited by 7
Solid Lipid Nanoparticles as an Innovative Lipidic Drug Delivery System
Waghmare, S., Palekar, R., Potey, L., Khedekar, P. B., Sabale, P., & Sabale, V. (2024) · Pharmaceutical Nanotechnology · doi:10.2174/0122117385271393231117063750 · Cited by 6
Pro Transferosome Loaded Gefitinib Novel Tablet for pulmonary drug delivery: Optimization and characterization
Swaroop, K., Basavaraju, S. B., Prasanthi, S., Prakash Goudanavar, S. O. P., Naveen, N. R., Sreeharsha, N., Meravanige, G., & Asif, A. H. (2024) · Journal of the Indian Chemical Society · doi:10.1016/j.jics.2024.101520 · Cited by 6
Magnetic and Quantum Dot Nanoparticles for Drug Delivery and Diagnostic Systems
Munasinghe, E., Aththapaththu, M., & Jayarathna, L. (2020) · IntechOpen eBooks · doi:10.5772/intechopen.88611 · Cited by 7
Preparation and characterization of slow dissolving linezolid salts for direct pulmonary delivery
Mori, D., jaroli, T., Dudhat, K. R., Vaishnav, D. J., Parmar, R., Kotadiya, N., Bhalodiya, M., & Pashavan, C. (2022) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2022.103741 · Cited by 6
Studies of the Specific Activity of Aerosolized Isoniazid against Tuberculosis in a Mouse Model
Valiulin, S. V., Onischuk, A. A., Baklanov, A. M., Dubtsov, S. N., Dultseva, G. G., An’kov, S. V., Tolstikova, T. G., Белогородцев, С. Н., & Schwartz, Y. S. (2022) · Antibiotics · doi:10.3390/antibiotics11111527 · Cited by 6
The Effects of Obesity on Lung Physiology, the Prevalence and Severity of Chronic Pulmonary Diseases, and Inhalation Treatment
Fröhlich, E. (2025) · Drug Design Development and Therapy · doi:10.2147/dddt.s564912 · Cited by 7
Enhanced pulmonary delivery of spray-dried theophylline: investigation of the trehalose and amino acid combinations as innovative fine carriers
Soliman, L., Party, P., Nagy, A., Farkas, Á., Paróczai, D., Burián, K., & Ambrus, R. (2025) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2025.107109 · Cited by 5
Clinical applications and future clinical trials of the drug delivery system
Çetin, K., Şarkaya, K., & Deni̇zli̇, A. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-95325-2.00020-1 · Cited by 5
Obtaining Tritium-Labeled Amikacin and Its Adsorption Immobilization on Functionalized Nanodiamonds
Solomatin, A. S., Yakovlev, R. Y., Leonidov, N. B., Badun, G. A., Chernysheva, M. G., Kulakova, I. I., Ставрианиди, А. Н., Shlyakhtin, O. A., & Лисичкин, Г. В. (2018) · Moscow University Chemistry Bulletin · doi:10.3103/s0027131418030082 · Cited by 5
pH-responsive microparticles of rifampicin for augmented intramacrophage uptake and enhanced antitubercular efficacy
Lokhande, A. S., Panchal, F. H., Munshi, R., Madkaikar, M. R., Malshe, V. C., & Devarajan, P. V. (2023) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2023.122729 · Cited by 6
Novel therapeutic approaches for targeting TB and HIV reservoirs prevailing in lungs
Jadhav, M., Khan, T. A., Bhavsar, C., Momin, M. M., & Omri, A. (2019) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2019.1621287 · Cited by 5
Physicochemical and Cytotoxicity Characterization of Injectable Bone Substitute Based on Hydroxyapatite - Chitosan - Streptomycin for Spinal Tuberculosis Cases
Rachmawati, S. A., Hikmawati, D., Budiatin, A. S., & Putra, A. P. (2019) · Materials science forum · doi:10.4028/www.scientific.net/msf.966.133 · Cited by 4
Liposome-Based Drug Delivery—A New Therapeutic Paradigm
Shetye, L. A., Sherlekar, A., & Mendhulkar, V. D. (2023) · Studies in mechanobiology, tissue engineering and biomaterials · doi:10.1007/978-981-99-6564-9_2 · Cited by 4
Formulation, characterization and evaluation of inhalable effervescent dry powder of Rifampicin nanoparticles
Rai, P. Y., Sansare, V. A., Warrier, D. U., & Shinde, U. A. (2022) · Indian Journal of Tuberculosis · doi:10.1016/j.ijtb.2022.03.007 · Cited by 4
Combined System for the Simultaneous Delivery of Levofloxacin and Rifampicin: Structural and Functional Properties and Antibacterial Activity
Le‐Deygen, I. M., Mamaeva, P. V., Скуредина, А. А., Safronova, A. S., Belogurova, N. G., & Kudryashova, E. V. (2023) · Journal of Functional Biomaterials · doi:10.3390/jfb14070381 · Cited by 5
The Influence of Chitosan Concentration on Polyelectrolytes Complexes (PECs) of Chitosan – Poly-2-Acrylamido-2-Methylprophane Sulfonic Acid (PAMPS) as Potential Drug Carrier in Pulmonary Delivery Application
Wibowo, A., Mumtaziah, Rachmawati, S. A., Qulub, F., Asri, L. A. T. W., Aimon, A. H., & Suratman, R. (2019) · IOP Conference Series Materials Science and Engineering · doi:10.1088/1757-899x/547/1/012028 · Cited by 4
Nanosponge as a drug delivery system
Ghourab, N., Gardouh, A. R., Gad, S., & Moustafa, Y. M. (2020) · Records of Pharmaceutical and Biomedical Sciences/Records of Pharmaceutical & Biomedical Sciences · doi:10.21608/rpbs.2019.17076.1041 · Cited by 4
Rifampicin‐Loaded Nano‐in‐Microparticles (Trojan Particles) as a Pulmonary Delivery System for Tuberculosis Treatment
Pham, D., Luong, V., Huynh, T. T. N., Huynh, D. T. M., & Phạm, D. T. (2024) · ChemNanoMat · doi:10.1002/cnma.202400296 · Cited by 3
Self-citation
Nanomedicines in Tuberculosis: Diagnosis, Therapy and Nanodrug Delivery
Dakkah, A. N., Bataineh, Y. A., Al-Jaidi, B. A., Bayan, M. F., & Nimer, N. A. (2020) · Engineering materials · doi:10.1007/978-3-030-36260-7_13 · Cited by 3
A Comprehensive Study of Multi-Drug Resistance in Tuberculosis
Sharma, M., & Kansal, S. (2022) · Advances in medical education, research, and ethics (AMERE) book series · doi:10.4018/978-1-7998-8490-3.ch016 · Cited by 3
Nano-bio Interactions in the Lung
Li, G., Liu, D., & Zuo, Y. (2023) · Micro/Nano technologies · doi:10.1007/978-981-16-8984-0_14 · Cited by 3
Current Drug Delivery Strategies to Design Orally Dissolving Formulations to Target Tuberculosis: A Futuristic Review
Chowrasia, P., Singh, M., Jana, B. K., Bora, P. L., Mahato, R. K., Kharbithai, R., Gogoi, N. R., Sarkar, T., Pal, P., & Mazumder, B. (2024) · Drug Delivery Letters · doi:10.2174/0122103031267044231031044456 · Cited by 3
Development of Liposomal Dry Powder Inhalation to Increase the Effectiveness of Tuberculosis Therapy
Nugraheni, R. W. (2022) · KnE Medicine · doi:10.18502/kme.v2i3.11921 · Cited by 3
Bibliometric Review on New Possibilities of Antimycobacterial Agents: Exploring Siderophore Desferrioxamine’s Applications as an Antimicrobial Agent
de Oliveira, P. V., Lira, R. D. S., Lima, R. D. A., Mendes, Y. C., Martins, A., de Melo, B. D. O., Goiano, M. F., Filho, R. L., Nunes, F. D. F., Aliança, A. S. D. S., et al. (2023) · Pharmaceuticals · doi:10.3390/ph16091335 · Cited by 3
Positron Emission Tomography-Computed Tomography Imaging of Selective Lobar Delivery of Stem Cells in Ex Vivo Lung Model of Mechanical Ventilation
Maracaja, L., Khanna, A. K., Murphy, S. V., Maracaja, D. L. V., Lane, M. R., Khoury, O., Tan, J. S., Damuka, N., Crawford, F. F., Bottoms, J. A., et al. (2023) · Journal of Aerosol Medicine and Pulmonary Drug Delivery · doi:10.1089/jamp.2022.0013 · Cited by 2
Exploring the Therapeutic Potential of 1,3-Benzimidazole: An Auspicious Heterocyclic Framework
Patel, S., Sen, A. K., Sen, D. B., & Shah, A. (2025) · Oriental Journal Of Chemistry · doi:10.13005/ojc/410202 · Cited by 2
Linezolid Delivery Methods to the Site of Tuberculosis Inflammation: a Systematic Review
Romanova, M. I., Gayda, А. I., Tyulkova, T. E., Sergeeva, V. I., Le‐Deygen, I. M., Kolmogorov, I. M., Avdeev, V. V., Можокина, Г. Н., & Samoylova, А. G. (2026) · Tuberculosis and lung diseases · doi:10.58838/2075-1230-2026-104-2-98-109 · Cited by 2
Poly(malic acid) Nanoconjugates of Pyrazinoic Acid for Lung Delivery in the Treatment of Tuberculosis
Nguyen, T. H. V., Tsapis, N., Benrabah, L., Gouilleux, B., Baltaze, J., Domenichini, S., Fattal, E., & Moine, L. (2024) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.4c00335 · Cited by 2
Self-citation
Inhalable polymeric dry powders for antituberculosis drug delivery
Adlakha, S., Vaghasiya, K., Sharma, A., Ray, E., & Verma, R. K. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-819811-7.00006-0 · Cited by 2
Formulation Strategies for Antitubercular Drugs by Inhalation
Buttini, F., & Colombo, G. (2016) · Wiley eBooks · doi:10.1002/9781118943182.ch10 · Cited by 2
Spray Drying Strategies to Stop Tuberculosis
Jennifer, W., Ricci, M., & Chan, H. (2016) · doi:10.1002/9781118943182.ch9 · Cited by 2
Analytical method development and validation for Simultaneous Estimation of Rifampicin and Levofloxacin in Bulk and Synthetic Mixtures Using Validated RP- HPLC Technique
Patil, P. R., & Patil, J. K. (2026) · Asian Journal of Pharmaceutical Analysis · doi:10.52711/2231-5675.2026.00004 · Cited by 1
Choline chloride-based deep eutectic solvents as solubility enhancers of antitubercular drug ethionamide
Blokhina, S. V., Ol’khovich, M. V., & Sharapova, A. V. (2026) · Journal of Molecular Liquids · doi:10.1016/j.molliq.2026.129486 · Cited by 1
Polymeric Fluoroquinolone Microparticles for Pulmonary Drug Delivery: A Review on Characteristics, Drug Release Profile, and Antibacterial Study
Deliaz, M. F., Hendradi, E., & Hariyadi, D. M. (2023) · International Journal of Drug Delivery Technology · doi:10.25258/ijddt.13.3.44 · Cited by 1
Targeted Delivery of Antibiotics Using Microparticles to Combat Multidrug-Resistant Tuberculosis
Upadhyay, T. K., Sharma, A., Fatima, N., Singh, A. K., Muttil, P., & Sharma, R. (2019) · Springer eBooks · doi:10.1007/978-981-13-9871-1_20 · Cited by 1
Nano-Bio Interactions in the Lung
Li, G., Liu, D., & Zuo, Y. (2022) · Micro/Nano technologies · doi:10.1007/978-981-13-9374-7_14-1 · Cited by 1
Combination drug delivery approaches for tuberculosis
Santos, F., & Duarte, A. R. C. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-85873-1.00006-x · Cited by 1
Spray drying strategies to stop tuberculosis
Jennifer, W., Maurizio, R., & Chan, H. (2016)
Clinical and Public Health Perspectives
Nathavitharana, R. R., & Nardell, E. A. (2016) · Wiley eBooks · doi:10.1002/9781118943182.ch19
Nanomedicines for the treatment of tuberculosis
Donnellan, S. (2016)
Experimental and theoretical studies on the particle formation process of particles for the improvement of pulmonary drug delivery
Baldelli, A. (2016) · ERA: Education and Research Archive (University of Alberta) · doi:10.7939/r3028pq3q
OVERCOMING CONTEMPORARY OBSTACLES IN DRUG DELIVERY VIA ACETALATED DEXTRAN PARTICLE FORMULATIONS
Shah, N. K. (2019) · doi:10.23860/diss-shah-nishan-2019
THE POTENTIAL ADVANTAGES OF SOLID LIPID NANOPARTICLES IN CHEMOTHERAPY OF TUBERCULOSIS
Sansare, V. A., & Kanavaje, A. M. (2019) · Indian Research Journal of Pharmacy and Science · doi:10.21276/irjps.2019.6.3.8
Nanotherapeutic platforms for osteoarticular tuberculosis
Osmani, R. A. M., Singh, E., Bhosale, R. R., Vaghela, R., & Patravale, V. B. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-819985-5.00006-1
Desenvolvimento e caracterização de micropartículas de quitosana para administração pulmonar de isoniazida
de Oliveira, P. M. (2016) · doi:10.26512/2016.07.d.21624
Pulmonary delivery for the treatment of tuberculosis
Poh, W. (2019) · doi:10.32657/10356/137335
Event groups
Ibrahim, D. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-821227-1.00012-8
Liposomes techniques of aerosolization for the treatment of obstructive, restrictive and infectious pulmonary diseases: a review
Santos, K. T. D. A., Macêdo, D. C. D. S., da Silva, L. B., & Nogueira, M. C. D. B. L. (2023) · Research Society and Development · doi:10.33448/rsd-v12i1.36950
Inhalation Therapy in Pulmonary Tuberculosis
Manning, T. J., Thomas-Richardson, J., Johnson, C. W., Patel, K., Thaker, Y., Thomas-Richardson, G., Philips, D., & Wylie, G. (2023) · Integrated science · doi:10.1007/978-3-031-15955-8_16
Environmental, Social, and Governance (ESG) Costs andMarket Performance of The Listed Agricultural Firms in Emerging Markets
Babatunde, O. F., Adebowale, I. O., Kolawole, O. A., Ogungbade, O. I., Awotomilusi, N. S., Arowolo, P. A., Ademola, M. A., Falana, G. A., Ogunleye, A. W., & Dagunduro, M. E. (2025) · International Journal of Accounting and Economics Studies · doi:10.14419/ysmzpp13
Pulmonary delivery of pyrazinamide nanoconjugates against tuberculosis
Nguyen, T. H. V. (2024) · theses.fr (ABES) · doi:10.70675/ee2a182fzb3d4z4c96zb51fz8ab8d78b0aa2
Investigation of cyclic peptides as drug delivery systems for the delivery of the anti-tuberculosis drug pyrazinamide
Makiabadi, B., Naderi, F., Zakarianezhad, M., & Raessi, A. (2026) · Nanoscale Advances · doi:10.1039/d5na01168j
Ruthenium complexes as potent antibiotics in methicillin-resistant Staphylococcus aureus (MRSA) via membrane damage
Wang, W.-P., Deng, W., Wang, J.-T., Liao, X.-W., Yu, R.-J., & Xiong, Y.-S. (2026) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2026.110463

Authors: Pham, D.-D., Fattal, E., & Tsapis, N.
Affiliations: Centre National de la Recherche Scientifique (FR)
Corresponding author: Pham, Dinh-Duy
Tsapis, Nicolas
ORCID: Fattal, Elias
Tsapis, Nicolas
Venue: International Journal of Pharmaceutics
Publisher: Elsevier BV
Published: 2015-01
Volume: 478
Issue: 2
Pages: 517-529
ISSN: 0378-5173 (ISSN-L)
DOI: 10.1016/j.ijpharm.2014.12.009
OpenAlex: W2076894650
Cited by: 185
References: 121
Citations by year: 2026: 5 · 2025: 11 · 2024: 11 · 2023: 23 · 2022: 15 · 2021: 12 · 2020: 26 · 2019: 25 · 2018: 16 · 2017: 14 · 2016: 18 · 2015: 9
FWCI: 2.34
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
Locations: International Journal of Pharmaceutics (publishedVersion)
PubMed (publishedVersion)
Funders: ANR (ANR-10-LABX-33)
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Inhalation and Respiratory Drug Delivery
Health Sciences › Medicine › Infectious Diseases › Tuberculosis Research and Epidemiology
Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
Keywords: pulmonary drug delivery, tuberculosis, antitubercular agents, dry powder inhaler, liposomes, microparticles, nanoparticles, alveolar macrophages, multidrug-resistant tuberculosis, medication adherence, controlled drug release, targeted drug delivery
MeSH terms: Administration, Inhalation, Animals, Antitubercular Agents, Humans, Powders, Tuberculosis, Pulmonary, Drug Delivery Systems

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Pulmonary drug delivery systems for tuberculosis treatment

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks